

Supplementary material

Table S1. The pseudo-sample after weighting on the propensity scores for the analysis related to the patient and graft survival (Abbreviations: ATG, Anti-Thymocyte Globulins; BSX, Basiliximab; sd, standard deviation)

	Global		ATG		BSX		Standardized difference (%)
	n	%	n	%	n	%	
Male recipient	285.3	74.6	130.2	74.3	155.1	74.8	1.1
History of cardiovascular disease	214.1	55.9	99.9	57.0	114.2	55.0	3.9
	mean	sd	mean	sd	mean	sd	
Recipient age (years)	71.0	4.9	70.8	4.8	71.1	5.0	5.1

Table S2. The pseudo-sample after weighting on the propensity scores for the analysis related to time to the first infection (Abbreviations: ATG, Anti-Thymocyte Globulins; BSX, Basiliximab; sd, standard deviation)

	Global		ATG		BSX		Standardized difference (%)
	n	%	n	%	n	%	
Preemptive transplantation	62.1	16.6	31.3	18.1	30.8	15.3	7.3
History of dyslipidemia	225.8	60.4	107.4	62.1	118.4	59.0	6.3
Male donor	168.7	45.2	71.8	41.5	96.9	48.3	13.6
Donor hypertension	214.2	57.3	96.5	55.8	117.6	58.6	5.7
Positive donor CMV serology	234.7	62.8	106.8	61.8	127.8	63.7	4.1
	mean	sd	mean	sd	mean	sd	
Recipient age (years)	71.1	4.9	71.0	4.7	71.2	5.0	3.2
Cold ischemia time (hours)	15.2	4.9	15.2	5.0	15.3	4.8	2.2

Table S3. The pseudo-sample after weighting on the propensity scores for the analysis related to time to the first BkV infection (Abbreviations: ATG, Anti-Thymocyte Globulins; BkV, Bk Virus; BSX, Basiliximab; sd, standard deviation)

	Whole sample		ATG		BSX		Standardized difference (%)
	n	%	n	%	n	%	
Positive donor CMV serology	234.4	61.6	107.6	60.3	126.8	62.7	4.9
	mean	sd	mean	sd	mean	sd	
Recipient age (years)	71.1	4.9	71.0	4.8	71.1	4.9	3.7
Cold ischemia time (hours)	15.3	5.0	15.2	5.1	15.3	4.9	1.7

Table S4. The pseudo-sample after weighting on the propensity scores for the analysis related to time to the first CMV infection (Abbreviations: ATG, Anti-Thymocyte Globulins; BSX, Basiliximab; CMV, Cytomegalovirus; sd, standard deviation)

	Global		ATG		BSX		Standardized difference (%)
	n	%	n	%	n	%	
History of hypertension	328.8	86.3	152.5	87.1	176.4	85.6	4.2
History of malignancy	107.0	28.1	51.2	29.2	55.8	27.1	4.7
Positive donor CMV serology	232.1	60.9	104.3	59.6	127.8	62.1	5.1

Table S5. The pseudo-sample after weighting on the propensity scores for the analysis related to time to the first bacterial infection (Abbreviations: ATG, Anti-Thymocyte Globulins; BSX, Basiliximab; sd, standard deviation)

	Global		ATG		BSX		Standardized difference (%)
	n	%	n	%	n	%	
Preemptive transplantation	64.8	17.4	30.7	17.9	34.1	16.9	2.6
History of vascular disease	114.8	30.8	56.1	32.8	58.7	29.1	8.0
History of dyslipidemia	224.1	60.1	105.7	61.7	118.3	58.6	6.3
Positive recipient EBV serology	357.6	95.8	162.5	94.8	195.1	96.7	9.3
Male donor	168.4	45.1	72.7	42.5	95.7	47.4	10.0
ECD donor	365.9	98.1	167.9	98.0	198.0	98.1	0.7
	mean	sd	mean	sd	mean	sd	
Cold ischemia time (hours)	15.2	5.0	15.1	5.1	15.3	4.9	3.3

Table S6. The pseudo-sample after weighting on the propensity scores for the analysis related to time to the first acute rejection episode (Abbreviations: ATG, Anti-Thymocyte Globulins; BSX, Basiliximab; sd, standard deviation)

	Global		ATG		BSX		Standardized difference (%)
	n	%	n	%	n	%	
History of vascular disease	109.6	29.9	51.2	31.0	58.4	29.0	4.4
Vascular cause of donor death	266.7	72.8	120.2	72.7	146.5	72.8	0.2
Donor hypertension	214.6	58.5	93.5	56.6	121.1	60.2	7.3
	mean	sd	mean	sd	mean	sd	
Cold ischemia time (hours)	15.3	5.0	15.2	5.1	15.4	5.0	4.4

Table S7. The pseudo-sample after weighting on the propensity scores for the analysis related to time to malignancy (Abbreviations: ATG, Anti-Thymocyte Globulins; BSX, Basiliximab; sd, standard deviation)

	Global		ATG		BSX		Standardized difference (%)
	n	%	n	%	n	%	
Male recipient	276.1	74.6	121.5	74.3	154.6	74.7	1.0
Preemptive transplantation	54.3	14.7	24.3	14.9	30.0	14.5	1.1
History of diabetes	126.7	34.2	54.8	33.5	71.9	34.8	2.6
History of cardiac disease	162.3	43.8	73.3	44.8	89.0	43.0	3.6
History of malignancy	103.8	28.0	48.5	29.7	55.3	26.7	6.5
Donor hypertension	214.6	57.9	92.5	56.6	122.1	59.0	5.0
Donor blood group							12.1
A	183.5	49.5	85.0	52.0	98.5	47.6	
AB	10.3	2.8	3.1	1.9	7.2	3.5	
B	28.8	7.8	12.6	7.7	16.2	7.8	
O	147.8	39.9	62.8	38.4	85.0	41.1	
	mean	sd	mean	sd	mean	sd	
Recipient age (years)	71.0	4.9	70.9	4.8	71.1	5.0	4.4

Table S8. The pseudo-sample after weighting on the propensity scores for the analysis related to time to PTD (Abbreviations: ATG, Anti-Thymocyte Globulins; BSX, Basiliximab; sd, standard deviation)

	Global		ATG		BSX		Standardized difference (%)
	n	%	n	%	n	%	
History of cardiovascular disease	123.1	48.3	54.2	48.1	68.9	48.5	0.8
Male donor	120.7	47.4	52.8	46.8	67.9	47.8	1.9
	mean	sd	mean	sd	mean	sd	
Recipient BMI (kg/m ²)	25.7	3.5	25.7	3.6	25.7	3.5	0.5
Donor age (years)	72.6	7.6	72.6	7.7	72.6	7.5	0.7
Cold ischemia time (hours)	15.6	4.9	15.6	5.0	15.6	4.9	0.8

Table S9. The pseudo-sample after weighting on the propensity scores for the analysis related to time to cardiac complication (Abbreviations: ATG, Anti-Thymocyte Globulins; BSX, Basiliximab; sd, standard deviation)

	Global		ATG		BSX		Standardized difference (%)
	n	%	n	%	n	%	
Male recipient	275.9	74.8	122.8	76.0	153.1	73.9	4.9
Recurrent causal nephropathy	62.5	17.0	27.2	16.8	35.3	17.0	0.6
History of hypertension	317.7	86.2	139.3	86.2	178.5	86.1	0.2
History of cardiovascular disease	207.6	56.3	95.2	58.9	112.4	54.2	9.5
History of B or C hepatitis	6.7	1.8	2.6	1.6	4.1	2.0	2.7
Donor hypertension	217.3	58.9	92.9	57.5	124.4	60.0	5.1
	mean	sd	mean	sd	mean	sd	
Recipient BMI (	26.7	4.0	26.6	4.0	26.7	4.0	0.7

Table S10. The pseudo-sample after weighting on the propensity scores for the analysis related to de novo DSA (Abbreviations: ATG, Anti-Thymocyte Globulins; BSX, Basiliximab; sd, standard deviation)

	Global		ATG		BSX		Standardized difference (%)
	n	%	n	%	n	%	
Recurrent causal nephropathy	28.5	13.9	9.8	13.7	18.7	14.0	0.9
History of cardiovascular disease	107.5	52.5	37.8	52.7	69.6	52.3	0.8
HLA-A-B-DR incompatibilities >4	52.6	25.7	18.2	25.3	34.4	25.8	1.2
	mean	sd	mean	sd	mean	sd	
Cold ischemia time (hours)	15.1	5.2	15.1	5.2	15.1	5.2	0.7

Table S11. The pseudo-sample after weighting on the propensity scores for the analysis related to the DGF occurrence (Abbreviations: ATG, Anti-Thymocyte Globulins; BSX, Basiliximab; DGF, Delayed Graft Function; sd, standard deviation)

	Global		ATG		BSX		Standardized difference (%)
	n	%	n	%	n	%	
History of vascular disease	101.5	36.9	52.7	37.2	48.8	36.4	1.7
History of cardiac disease	125.4	45.5	68.7	48.5	56.7	42.4	12.5
Male donor	130.3	47.3	69.4	49.1	60.9	45.5	7.2
	mean	sd	mean	sd	mean	sd	
Recipient BMI (kg/m ²)	27.0	3.9	26.9	4.0	27.0	3.9	3.8
Donor creatininemia (μmol/l)	80.3	37.2	81.3	38.9	79.3	35.6	5.6
Cold ischemia time (hours)	15.1	4.9	14.9	5.0	15.2	4.8	5.5

Table S12. Comparison of the included patients versus excluded patients because of diabetes history at transplantation (Abbreviations: BMI, body mass index; CMV, cytomegalovirus; EBV, Epstein-Barr virus; ECD, Expanded criteria donor; HLA, human leucocyte antigen; NA, not available (missing); sd, standard deviation)

	Global (n=383)			Included (n=260)			Excluded (n=123)			p-value
	NA	n	%	NA	n	%	NA	n	%	
Male recipient	0	284	74.2	0	187	71.9	0	97	78.9	0.1475
Recurrent causal nephropathy	0	63	16.4	0	54	20.8	0	9	7.3	0.0009
Preemptive transplantation	1	61	16.0	0	48	18.5	1	13	10.7	0.0522
History of hypertension	0	327	85.4	0	220	84.6	0	107	87.0	0.5388
History of vascular disease	0	109	28.5	0	69	26.5	0	40	32.5	0.2257
History of cardiac disease	0	153	39.9	0	94	36.2	0	59	48.0	0.0275
History of cardiovascular disease	0	203	53.0	0	128	49.2	0	75	61.0	0.0315
History of malignancy	0	94	24.5	0	72	27.7	0	22	17.9	0.0373
History of dyslipidemia	0	220	57.4	0	140	53.8	0	80	65.0	0.0386
Positive recipient CMV serology	5	230	60.8	4	149	58.2	1	81	66.4	0.1272
Male donor	0	187	48.8	0	125	48.1	0	62	50.4	0.6702
ECD donor	1	372	97.4	1	253	97.7	0	119	96.7	0.7328
Vascular cause of donor death	0	275	71.8	0	187	71.9	0	88	71.5	0.9388
Donor hypertension	11	224	60.2	10	152	60.8	1	72	59.0	0.7414
Positive donor CMV serology	0	240	62.7	0	159	61.2	0	81	65.9	0.3746
Positive donor EBV serology	1	370	96.9	1	250	96.5	0	120	97.6	0.7585
HLA-A-B-DR incompatibilities >4	5	97	25.7	2	65	25.2	3	32	26.7	0.7602
	NA	m	sd	NA	m	sd	NA	m	sd	
Recipient age (years)	0	70.8	4.8	0	70.5	4.6	0	71.2	5.0	0.1970
Recipient BMI (kg/m ²)	3	26.7	4.0	2	25.7	3.6	1	28.8	4.1	<0.0001
Duration on waiting list (months)	16	16.5	19.0	10	17.2	19.7	6	15.1	17.4	0.3115
Donor age (years)	1	72.7	8.8	1	72.6	7.9	0	72.9	10.5	0.7651
Donor creatininemia (μmol/l)	1	82.9	39.5	1	81.5	36.5	0	86.0	45.2	0.3287
Cold ischemia time (hours)	3	15.6	5.0	2	15.7	5.0	1	15.4	4.9	0.6349

Table S13. Comparison of the included patients versus excluded patients because of missing data on eGFR value at 1-year posttransplantation (Abbreviations: BMI, body mass index; CMV, cytomegalovirus; EBV, Epstein-Barr virus; ECD, Expanded criteria donor; HLA, human leucocyte antigen; NA, not available (missing); sd, standard deviation)

	Global (n=383)			Included (n=279)			Excluded (n=104)			p-value
	NA	n	%	NA	n	%	NA	n	%	
Male recipient	0	284	74.2	0	208	58.6	0	76	73.1	0.7693
Recurrent causal nephropathy	0	63	16.4	0	46	12.0	0	17	16.3	0.9735
Preemptive transplantation	1	61	16.0	1	46	12.0	0	15	14.4	0.6140
History of diabetes	0	123	32.1	0	91	23.8	0	32	30.8	0.7306
History of hypertension	0	327	85.4	0	235	61.4	0	92	88.5	0.2971
History of vascular disease	0	109	28.5	0	77	20.1	0	32	30.8	0.5408
History of cardiac disease	0	153	39.9	0	113	29.5	0	40	38.5	0.7169
History of cardiovascular disease	0	203	53.0	0	147	38.4	0	56	53.8	0.8400
History of malignancy	0	94	24.5	0	71	18.5	0	23	22.1	0.5003
History of dyslipidemia	0	220	57.4	0	163	42.6	0	57	54.8	0.5245
Positive recipient CMV serology	5	230	60.8	3	163	42.9	2	67	65.7	0.2412
Male donor	0	187	48.8	0	144	37.6	0	43	41.3	0.0738
ECD donor	1	372	97.4	1	271	70.9	0	101	97.1	0.2854
Vascular cause of donor death	0	275	71.8	0	202	52.7	0	73	70.2	0.6691
Donor hypertension	11	224	60.2	4	170	44.9	7	54	55.7	0.2875
Positive donor CMV serology	0	240	62.7	0	174	45.4	0	66	63.5	0.8437
Positive donor EBV serology	1	370	96.9	1	269	70.4	0	101	97.1	1.0000
HLA-A-B-DR incompatibilities >4	5	97	25.7	4	65	17.2	1	32	31.1	0.1408
	NA	m	sd	NA	m	sd	NA	m	sd	
Recipient age (years)	0	70.8	4.8	0	70.2	4.5	0	72.2	5.2	0.0011
Recipient BMI (kg/m ²)	3	26.7	4.0	2	26.9	4.1	1	26.1	3.8	0.0596
Duration on waiting list (months)	16	16.5	19.0	14	15.7	15.4	2	18.8	26.3	0.2646
Donor age (years)	1	72.7	8.8	1	72.3	8.6	0	73.6	9.2	0.1980
Donor creatininemia (μmol/l)	1	82.9	39.5	1	84.5	41.9	0	78.9	31.9	0.1676
Cold ischemia time (hours)	3	15.6	5.0	2	15.4	5.1	1	16.0	4.7	0.3069

Table S14. Comparison of the included patients versus excluded patients because of preemptive transplantation or peritoneal dialysis as renal replacement therapy or missing data on the DGF value (Abbreviations: BMI, body mass index; CMV, cytomegalovirus; EBV, Epstein-Barr virus; ECD, Expanded criteria donor; HLA, human leucocyte antigen; NA, not available (missing); sd, standard deviation)

	Global (n=383)			Included (n=280)			Excluded (n=103)			p-value
	NA	n	%	NA	n	%	NA	n	%	
Male recipient	0	284	74.2	0	204	72.9	0	80	77.7	0.3401
Recurrent causal nephropathy	0	63	16.4	0	42	15.0	0	21	20.4	0.2072
Preemptive transplantation	1	61	16.0	0	0	0.0	1	61	59.8	<0.0001
History of diabetes	0	123	32.1	0	99	35.4	0	24	23.3	0.0251
History of hypertension	0	327	85.4	0	234	83.6	0	93	90.3	0.0989
History of vascular disease	0	109	28.5	0	84	30.0	0	25	24.3	0.2706
History of cardiac disease	0	153	39.9	0	109	38.9	0	44	42.7	0.5019
History of cardiovascular disease	0	203	53.0	0	150	53.6	0	53	51.5	0.7131
History of malignancy	0	94	24.5	0	64	22.9	0	30	29.1	0.2062
History of dyslipidemia	0	220	57.4	0	154	55.0	0	66	64.1	0.1111
Positive recipient CMV serology	5	230	60.8	4	174	63.0	1	56	54.9	0.1500
Male donor	0	187	48.8	0	143	51.1	0	44	42.7	0.1470
ECD donor	1	372	97.4	1	271	97.1	0	101	98.1	1.0000
Vascular cause of donor death	0	275	71.8	0	197	70.4	0	78	75.7	0.3003
Donor hypertension	11	224	60.2	5	156	56.7	6	68	70.1	0.0207
Positive donor CMV serology	0	240	62.7	0	174	62.1	0	66	64.1	0.7285
Positive donor EBV serology	1	370	96.9	0	270	96.4	1	100	98.0	0.5277
HLA-A-B-DR incompatibilities >4	5	97	25.7	3	73	26.4	2	24	23.8	0.6097
	NA	m	sd	NA	m	sd	NA	m	sd	
Recipient age (years)	0	70.8	4.8	0	70.6	4.8	0	71.3	4.7	0.1516
Recipient BMI (kg/m ²)	3	26.7	4.0	2	26.9	4.1	1	26.2	3.8	0.1166
Duration on waiting list (months)	16	16.5	19.0	12	18.0	20.6	4	12.4	13.2	0.0024
Donor age (years)	1	72.7	8.8	1	72.1	9.1	0	74.2	7.5	0.0221
Donor creatininemia (μmol/l)	1	82.9	39.5	1	83.6	41.2	0	81.2	34.5	0.5636
Cold ischemia time (hours)	3	15.6	5.0	1	15.5	4.8	2	15.8	5.5	0.5947




Figure S1. Propensity score distribution. **A**-Patient and graft survival. **B**-Time to first infection. **C**-Time to BKV infection




Figure S2. Propensity score distribution. **A**-Time to CMV infection. **B**-Time to bacterial infection. **C**-Time to first acute rejection episode.




Figure S3. Propensity score distribution. **A**-Time to malignancy. **B**-Time to PTD. **C**-Time to cardiac complication.




Figure S4. Propensity score distribution. **A-** de novo DSA. **B-**DGF.




Figure S5. Estimated Glomerular Filtration Rate (eGFR) at 1-year posttransplantation among the 279 patients alive and followed-up at the first anniversary of the transplantation.